STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Employers plan to drop coverage of GLP‑1 weight‑loss drugs in 2027 as usage rises, offsetting savings from lower prices of Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo (Reuters).
- Business Group on Health reports that about 10 % of employers currently covering GLP‑1 drugs intend to discontinue coverage in 2027.
- Mercer finds that 5 % of large employers (≥ 500 employees) will drop GLP‑1 coverage in 2027, while 44 % of such firms already cover the drugs for obesity.
- Business Group on Health data show that 67 % of large employers will cover GLP‑1s in 2026.
- UK households with at least one GLP‑1 user reduced grocery purchases by 299 million items in the year after starting the medication, according to a Worldpanel study by Numerator.
- Worldpanel/Numerator study notes that GLP‑1 usage in the UK has nearly tripled over two years, rising to 6.3 % of households in 2026 from 4.1 % in 2025 and 2.3 % in 2024.
Why it matters: Employers risk higher out‑of‑pocket costs for employees as coverage shrinks, while workers lose a subsidized weight‑loss option; UK grocery retailers see a $1 billion sales dip, highlighting how drug adoption reshapes both health‑benefit budgets and consumer spending patterns, and may pressure insurers to renegotiate pricing.
